161 related articles for article (PubMed ID: 19705874)
1. Nonproteolytic induction of catalytic activity into the single-chain form of urokinase-type plasminogen activator by dipeptides.
Bøtkjaer KA; Byszuk AA; Andersen LM; Christensen A; Andreasen PA; Blouse GE
Biochemistry; 2009 Oct; 48(40):9606-17. PubMed ID: 19705874
[TBL] [Abstract][Full Text] [Related]
2. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
[TBL] [Abstract][Full Text] [Related]
3. A cyclic peptidylic inhibitor of murine urokinase-type plasminogen activator: changing species specificity by substitution of a single residue.
Andersen LM; Wind T; Hansen HD; Andreasen PA
Biochem J; 2008 Jun; 412(3):447-57. PubMed ID: 18318660
[TBL] [Abstract][Full Text] [Related]
4. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.
Liu JN; Tang W; Sun ZY; Kung W; Pannell R; Sarmientos P; Gurewich V
Biochemistry; 1996 Nov; 35(45):14070-6. PubMed ID: 8916892
[TBL] [Abstract][Full Text] [Related]
5. Rezymogenation of active urokinase induced by an inhibitory antibody.
Jiang L; Botkjaer KA; Andersen LM; Yuan C; Andreasen PA; Huang M
Biochem J; 2013 Jan; 449(1):161-6. PubMed ID: 23016918
[TBL] [Abstract][Full Text] [Related]
6. A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
Egelund R; Petersen TE; Andreasen PA
Eur J Biochem; 2001 Feb; 268(3):673-85. PubMed ID: 11168406
[TBL] [Abstract][Full Text] [Related]
7. Hydrophobic interactions control zymogen activation in the trypsin family of serine proteases.
Hedstrom L; Lin TY; Fast W
Biochemistry; 1996 Apr; 35(14):4515-23. PubMed ID: 8605201
[TBL] [Abstract][Full Text] [Related]
8. Mutagenesis at Pro309 of single-chain urokinase-type plasminogen activator alters its catalytic properties.
Sun Z; Liu JN
Proteins; 2005 Dec; 61(4):870-7. PubMed ID: 16231330
[TBL] [Abstract][Full Text] [Related]
9. Interconversion of active and inactive conformations of urokinase-type plasminogen activator.
Liu Z; Kromann-Hansen T; Lund IK; Hosseini M; Jensen KJ; Høyer-Hansen G; Andreasen PA; Sørensen HP
Biochemistry; 2012 Oct; 51(39):7804-11. PubMed ID: 22950516
[TBL] [Abstract][Full Text] [Related]
10. Prevention of beta strand movement into a zymogen-like position does not confer higher activity to coagulation factor VIIa.
Olsen OH; Nielsen PF; Persson E
Biochemistry; 2004 Nov; 43(44):14096-103. PubMed ID: 15518559
[TBL] [Abstract][Full Text] [Related]
11. A ribonuclease zymogen activated by the NS3 protease of the hepatitis C virus.
Johnson RJ; Lin SR; Raines RT
FEBS J; 2006 Dec; 273(23):5457-65. PubMed ID: 17116245
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
[TBL] [Abstract][Full Text] [Related]
14. A novel mode of intervention with serine protease activity: targeting zymogen activation.
Blouse GE; Bøtkjaer KA; Deryugina E; Byszuk AA; Jensen JM; Mortensen KK; Quigley JP; Andreasen PA
J Biol Chem; 2009 Feb; 284(7):4647-57. PubMed ID: 19047064
[TBL] [Abstract][Full Text] [Related]
15. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
16. Structure of human pro-chymase: a model for the activating transition of granule-associated proteases.
Reiling KK; Krucinski J; Miercke LJ; Raymond WW; Caughey GH; Stroud RM
Biochemistry; 2003 Mar; 42(9):2616-24. PubMed ID: 12614156
[TBL] [Abstract][Full Text] [Related]
17. Recombinant production of a hybrid plasminogen activator composed of surfactant protein B and low-molecular-weight urokinase.
Ruppert C; Mahavadi P; Wygrecka M; Weaver TE; Magdolen V; Idell S; Preissner KT; Seeger W; Günther A; Markart P
Thromb Haemost; 2008 Dec; 100(6):1185-92. PubMed ID: 19132247
[TBL] [Abstract][Full Text] [Related]
18. Human/chicken urokinase chimeras demonstrate sequences outside the serine protease domain that dictate autoactivation.
Aimes RT; Regazzoni K; Quigley JP
Thromb Haemost; 2003 Feb; 89(2):382-92. PubMed ID: 12574820
[TBL] [Abstract][Full Text] [Related]
19. Structure and function of microplasminogen: II. Determinants of activation by urokinase and by the bacterial activator streptokinase.
Wang J; Reich E
Protein Sci; 1995 Sep; 4(9):1768-79. PubMed ID: 8528075
[TBL] [Abstract][Full Text] [Related]
20. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
Spraggon G; Phillips C; Nowak UK; Ponting CP; Saunders D; Dobson CM; Stuart DI; Jones EY
Structure; 1995 Jul; 3(7):681-91. PubMed ID: 8591045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
